For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  HGH Fragment 176-191
Weight & Metabolicpreclinical

HGH Fragment 176-191

hGH 176-191
Weight & Metabolic
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Weight & Metabolic
Evidence grade
D
PubMed records
3
Female-tagged
1
Sex-analysis
0
CAS
—
D
Evidence grade D, Preclinical / animal evidence only across 3 indexed studies. No human trial data. How grades work →
Female evidence: None
HGH Fragment 176-191: of 3 PubMed records, 1 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of the human growth-hormone molecule. By isolating this short segment rather than the full hormone, researchers obtain a more defined tool compound for studying a specific slice of growth-hormone biology.

In preclinical and in-vitro systems, the fragment has been studied for lipolytic signaling, meaning the metabolic pathways associated with fat breakdown, apart from the broader growth-promoting activity of intact growth hormone. Researchers characterizing metabolic mechanisms have used it as a research material to examine how this region of the molecule behaves in isolation.

What makes HGH Fragment 176-191 a useful entry for a weight and metabolic catalog is exactly this separation of one studied pathway from the parent hormone's wider effects. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women. Supplied for laboratory research use only.

Summary

HGH Fragment 176-191 is the unmodified C-terminal lipolytic fragment of human growth hormone. Direct study of this exact entity is minimal, most data concern its stabilized analog AOD-9604, which failed to beat placebo in obesity trials. There is no human efficacy or female-specific evidence for the fragment itself.

Evidence in women

Menstrual cycle
Unstudied
No studies examine menstrual cycle interactions.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data exist.
Hormonal interactions
Unstudied
No data on reproductive- or thyroid-hormone interactions.
Perimenopause & menopause
Unstudied
No perimenopausal or menopausal data.
Sex differences
Unstudied
There is essentially no direct indexed study of this fragment, so no sex-difference data.

Mechanism

Proposed to stimulate fat breakdown (lipolysis) via the C-terminal region of growth hormone, without the growth-promoting effects of the full hormone.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)No established human dose; lipolytic activity described mainly in preclinical and analog (AOD-9604) work.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: insufficient data to characterize

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

insufficient human data to characterize

HGH Fragment 176-191 reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for HGH Fragment 176-191

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from HGH Fragment 176-191's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is HGH Fragment 176-191?

HGH Fragment 176-191, also known as hGH 176-191, is a research compound in our weight metabolic category. HGH Fragment 176-191 is the unmodified C-terminal lipolytic fragment of human growth hormone.

Is HGH Fragment 176-191 studied in women?

HGH Fragment 176-191: of 3 PubMed records, 1 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this none: no PubMed record for HGH Fragment 176-191 is tagged as including female subjects, so its effects in women are effectively unstudied. That blank is the finding, not a safety signal, and we do not fill it with guesses.

Has HGH Fragment 176-191 been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data exist. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does HGH Fragment 176-191 have, and why?

HGH Fragment 176-191 carries evidence grade D. Preclinical / animal evidence only across 3 indexed studies. No human trial data.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for HGH Fragment 176-191?

No. A female-specific dose for HGH Fragment 176-191 is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is HGH Fragment 176-191 administered in research?

In the published literature, HGH Fragment 176-191 is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for HGH Fragment 176-191?

Effects reported in the research literature include insufficient human data to characterize. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should HGH Fragment 176-191 be stored and handled?

HGH Fragment 176-191 sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy HGH Fragment 176-191 for research?

HGH Fragment 176-191 is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: HGH Fragment 176-191 isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Citations (PMID)

42395176

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.